Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

Cardiovascular disease is a leading cause of death and reduced quality of life, proven by
the latest data of the Global Burden of Disease Study, and is only gaining in prevalence …

Aims/hypothesis: SGLT-2 inhibitors (SGLT-2i) have been studied as potential treatments
against NAFLD, showing varying beneficial effects. The molecular mechanisms mediating …

Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as
frequent in patients with diabetes compared with those who do not have diabetes. Moreover …

Background Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the
main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 …

Ischemic heart disease (IHD) is the leading cause of disability and mortality worldwide.
Reactive oxygen species (ROS) have been shown to play key roles in the progression of …

Impaired cardiac microvascular function contributes to diabetic cardiovascular complications
although effective therapy remains elusive. Empagliflozin, a sodium-glucose cotransporter 2 …

Non-alcoholic fatty liver disease (NAFLD) is an 'umbrella'term, comprising a spectrum
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …

OBJECTIVE To assess whether the sodium–glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin improves cognitive impairment in frail older adults with diabetes and heart …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …